Sector News

Lilly challenges Wegovy dominance in weight loss market with FDA approval

November 11, 2023
Life sciences

Eli Lilly’s Zepbound (tirzepatide) has received approval from the US Food and Drug Administration (FDA) for the treatment of overweight or obese adults with weight-related medical problems.

The drug also received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for weight loss and weight management.

Zepbound is an incretin hormone receptor agonist that targets glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It has previously been approved by the FDA for the treatment of type 2 diabetes and is sold as Mounjaro.

Weight loss management is a growing market, with Novo Nordisk being the market leader in the field. The company’s weight loss drugs, Wegovy (semaglutide) and Saxenda (liraglutide), generated Dkr30.4bn ($4.36bn) in combined global sales in the first nine months of 2023, as per Novo Nordisk’s Q3 financials.

Lilly has set Zepbound’s list price in the US at $1,059.87, approximately 20% less than that for Wegovy, which has a list price of $1,349.02, as per an 8 November press release. Lilly plans to launch the drug in the US in six doses, ranging from 2.5mg to 15mg, by the end of this year.

Zepbound’s FDA approval was based on the results from the Phase III SURMOUNT-1 and SURMOUNT-2 trials. The 2,539 participants evaluated in the SURMOUNT-1 trial (NCT04184622) demonstrated average weight loss of 34lb and 48lb with 5mg and 15mg of Zepbound, respectively.

Zepbound is indicated for use in addition to a reduced-calorie diet and increased physical activity. The drug use is cautioned in patients with a history of pancreatitis, or with severe gastrointestinal disease, and for use in conjunction with other tripeptide-containing or GLP-1 receptor agonist drugs.

Zepbound carries a boxed warning for thyroid C-cell tumours. The drug is contraindicated in adults with a personal or family history of medullary thyroid carcinoma, in patients with multiple endocrine neoplasia syndrome type 2, and in adults with known serious hypersensitivity to tirzepatide or any of the excipients in Zepbound, as per an 8 November press release.

by Phalguni Deswal


comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach